Cargando…
A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women
OBJECTIVE—Subclinical inflammation is linked with the development of type 2 diabetes, and epidemiologic data suggest that this association may be stronger in women. Although small clinical studies have shown a prominent hypoglycemic effect of short-term high-dose aspirin, no randomized trials have d...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606820/ https://www.ncbi.nlm.nih.gov/pubmed/18835953 http://dx.doi.org/10.2337/dc08-1206 |
_version_ | 1782162988713639936 |
---|---|
author | Pradhan, Aruna D. Cook, Nancy R. Manson, JoAnn E. Ridker, Paul M. Buring, Julie E. |
author_facet | Pradhan, Aruna D. Cook, Nancy R. Manson, JoAnn E. Ridker, Paul M. Buring, Julie E. |
author_sort | Pradhan, Aruna D. |
collection | PubMed |
description | OBJECTIVE—Subclinical inflammation is linked with the development of type 2 diabetes, and epidemiologic data suggest that this association may be stronger in women. Although small clinical studies have shown a prominent hypoglycemic effect of short-term high-dose aspirin, no randomized trials have directly evaluated the efficacy of aspirin in diabetes prevention at doses acceptable for use in routine clinical practice. We evaluated whether chronic low-dose aspirin prevents the development of clinical diabetes among initially healthy American women. RESEARCH DESIGN AND METHODS—Subjects were enrolled in the Women's Health Study, a 10-year randomized double-blind, placebo-controlled trial of aspirin and vitamin E for primary prevention of cardiovascular disease and cancer. Between 1992 and 1995, 38,716 women aged ≥45 years and free of clinical diabetes were randomly assigned to either low-dose aspirin or placebo (median follow-up 10.2 years). Documented clinical type 2 diabetes was prospectively evaluated throughout the trial. RESULTS—Among women randomly assigned to receive aspirin (n = 19,326) or placebo (n = 19,390), there was no statistically significant difference in the incidence of type 2 diabetes. There were 849 cases of diabetes in the aspirin group and 847 in the placebo group (rate ratio 1.01 [95% CI 0.91–1.11]). Stratification by diabetes risk factors including age, BMI, family history of diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not support a modulating effect of these variables. Analyses accounting for treatment duration and adherence similarly found no beneficial effects. CONCLUSIONS—These data suggest that long-term low-dose aspirin does not prevent the development of clinical type 2 diabetes in initially healthy women. |
format | Text |
id | pubmed-2606820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-26068202010-01-01 A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women Pradhan, Aruna D. Cook, Nancy R. Manson, JoAnn E. Ridker, Paul M. Buring, Julie E. Diabetes Care Clinical Care/Education/Nutrition/Psychosocial Research OBJECTIVE—Subclinical inflammation is linked with the development of type 2 diabetes, and epidemiologic data suggest that this association may be stronger in women. Although small clinical studies have shown a prominent hypoglycemic effect of short-term high-dose aspirin, no randomized trials have directly evaluated the efficacy of aspirin in diabetes prevention at doses acceptable for use in routine clinical practice. We evaluated whether chronic low-dose aspirin prevents the development of clinical diabetes among initially healthy American women. RESEARCH DESIGN AND METHODS—Subjects were enrolled in the Women's Health Study, a 10-year randomized double-blind, placebo-controlled trial of aspirin and vitamin E for primary prevention of cardiovascular disease and cancer. Between 1992 and 1995, 38,716 women aged ≥45 years and free of clinical diabetes were randomly assigned to either low-dose aspirin or placebo (median follow-up 10.2 years). Documented clinical type 2 diabetes was prospectively evaluated throughout the trial. RESULTS—Among women randomly assigned to receive aspirin (n = 19,326) or placebo (n = 19,390), there was no statistically significant difference in the incidence of type 2 diabetes. There were 849 cases of diabetes in the aspirin group and 847 in the placebo group (rate ratio 1.01 [95% CI 0.91–1.11]). Stratification by diabetes risk factors including age, BMI, family history of diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not support a modulating effect of these variables. Analyses accounting for treatment duration and adherence similarly found no beneficial effects. CONCLUSIONS—These data suggest that long-term low-dose aspirin does not prevent the development of clinical type 2 diabetes in initially healthy women. American Diabetes Association 2009-01 /pmc/articles/PMC2606820/ /pubmed/18835953 http://dx.doi.org/10.2337/dc08-1206 Text en Copyright © 2009, American Diabetes Association https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Clinical Care/Education/Nutrition/Psychosocial Research Pradhan, Aruna D. Cook, Nancy R. Manson, JoAnn E. Ridker, Paul M. Buring, Julie E. A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women |
title | A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women
|
title_full | A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women
|
title_fullStr | A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women
|
title_full_unstemmed | A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women
|
title_short | A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women
|
title_sort | randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women |
topic | Clinical Care/Education/Nutrition/Psychosocial Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606820/ https://www.ncbi.nlm.nih.gov/pubmed/18835953 http://dx.doi.org/10.2337/dc08-1206 |
work_keys_str_mv | AT pradhanarunad arandomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT cooknancyr arandomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT mansonjoanne arandomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT ridkerpaulm arandomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT buringjuliee arandomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT pradhanarunad randomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT cooknancyr randomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT mansonjoanne randomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT ridkerpaulm randomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen AT buringjuliee randomizedtrialoflowdoseaspirininthepreventionofclinicaltype2diabetesinwomen |